{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:58:22Z","timestamp":1773849502816,"version":"3.50.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,4,15]],"date-time":"2014-04-15T00:00:00Z","timestamp":1397520000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/bjc.2014.197","type":"journal-article","created":{"date-parts":[[2014,4,15]],"date-time":"2014-04-15T20:02:20Z","timestamp":1397592140000},"page":"2396-2404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis"],"prefix":"10.1038","volume":"110","author":[{"given":"Z","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,15]]},"reference":[{"issue":"4","key":"BFbjc2014197_CR1","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","volume":"72","author":"A Al-Mamgani","year":"2008","unstructured":"Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (4): 980\u2013988.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"BFbjc2014197_CR2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ijrobp.2009.12.039","volume":"79","author":"A Al-Mamgani","year":"2011","unstructured":"Al-Mamgani A, van Putten WL, van der Wielen GJ, Levendag PC, Incrocci L (2011) Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int J Radiat Oncol Biol Phys 79 (4): 1004\u20131012.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"BFbjc2014197_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijrobp.2009.01.030","volume":"76","author":"A Alexander","year":"2010","unstructured":"Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C (2010) Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3-versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 76 (1): 23\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"BFbjc2014197_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ijrobp.2009.12.045","volume":"79","author":"G Arcangeli","year":"2011","unstructured":"Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, Benassi M, Strigari L (2011) Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79 (4): 1013\u20131021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"BFbjc2014197_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","volume":"78","author":"G Arcangeli","year":"2010","unstructured":"Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J, Strigari L (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78 (1): 11\u201318.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"BFbjc2014197_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","volume":"84","author":"S Arcangeli","year":"2012","unstructured":"Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnar\u00f2 P, Pinzi V, Arcangeli G (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84 (5): 1172\u20131178.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"BFbjc2014197_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijrobp.2010.04.065","volume":"81","author":"JG Armstrong","year":"2011","unstructured":"Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME, Taylor JC, O'Shea CM, Buckney SJ, Thirion PG (2011) A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 81 (1): 35\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"BFbjc2014197_CR8","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.ejca.2003.12.027","volume":"40","author":"F Ataman","year":"2004","unstructured":"Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, Dubois JB, Jeanneret W, Keuppens F, Bernier J (2004) Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 40 (11): 1674\u20131681.","journal-title":"Eur J Cancer"},{"issue":"7","key":"BFbjc2014197_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clon.2012.05.002","volume":"24","author":"G Bauman","year":"2012","unstructured":"Bauman G, Rumble R, Chen J, Loblaw A, Warde P (2012) Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 24 (7): 461\u2013473.","journal-title":"Clin Oncol"},{"issue":"4","key":"BFbjc2014197_CR10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","volume":"80","author":"V Beckendorf","year":"2011","unstructured":"Beckendorf V, Guerif S, Le Pris\u00e9 E, Cosset J-M, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud J-M (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80 (4): 1056\u20131063.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"BFbjc2014197_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ijrobp.2004.05.033","volume":"60","author":"V Beckendorf","year":"2004","unstructured":"Beckendorf V, Gu\u00e9rif S, Le Pris\u00e9 E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM (2004) The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 (4): 1056\u20131065.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9327","key":"BFbjc2014197_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (9327): 103\u2013108.","journal-title":"Lancet"},{"issue":"24","key":"BFbjc2014197_CR13","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, De Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G (2009) Duration of androgen suppression in the treatment of prostate cancer. New Engl J Med 360 (24): 2516\u20132527.","journal-title":"New Engl J Med"},{"issue":"5","key":"BFbjc2014197_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJM199707313370502","volume":"337","author":"M Bolla","year":"1997","unstructured":"Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Gil T (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 337 (5): 295\u2013300.","journal-title":"New Engl J Med"},{"issue":"11","key":"BFbjc2014197_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11 (11): 1066\u20131073.","journal-title":"Lancet Oncol"},{"key":"BFbjc2014197_CR16","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2011) Introduction to Meta-analysis Wiley.com."},{"issue":"1","key":"BFbjc2014197_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1477-7525-10-123","volume":"10","author":"JL Bosco","year":"2012","unstructured":"Bosco JL, Halpenny B, Berry DL (2012) Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer. Health Qual Life Outcomes 10 (1): 123.","journal-title":"Health Qual Life Outcomes"},{"key":"BFbjc2014197_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CE.S41178","volume":"8","author":"TE Botrel","year":"2013","unstructured":"Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Dos Reis RB (2013) Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis. Core Evidence 8: 1\u201313.","journal-title":"Core Evidence"},{"issue":"15","key":"BFbjc2014197_CR19","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.24392","volume":"115","author":"E Bria","year":"2009","unstructured":"Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnar\u00f2 P, Terzoli E, Cognetti F, Carlini P (2009) Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Cancer 115 (15): 3446\u20133456.","journal-title":"Cancer"},{"issue":"6","key":"BFbjc2014197_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50 (6): 683\u2013691.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"BFbjc2014197_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jclinepi.2009.08.025","volume":"63","author":"DM Caldwell","year":"2010","unstructured":"Caldwell DM, Welton NJ, Ades A (2010) Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J Clin Epidemiol 63 (8): 875\u2013882.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"BFbjc2014197_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.radonc.2005.10.005","volume":"77","author":"D Christie","year":"2005","unstructured":"Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C (2005) Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 77 (2): 117\u2013125.","journal-title":"Radiother Oncol"},{"issue":"9665","key":"BFbjc2014197_CR23","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","volume":"373","author":"A Cipriani","year":"2009","unstructured":"Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins J, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373 (9665): 746\u2013758.","journal-title":"Lancet"},{"issue":"7","key":"BFbjc2014197_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28 (7): 1117\u20131123.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014197_CR25","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S0360-3016(96)00584-6","volume":"37","author":"J Cox","year":"1997","unstructured":"Cox J, Kaplan G American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035\u20131041.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"BFbjc2014197_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (5): 1341\u20131346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"BFbjc2014197_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijrobp.2004.02.022","volume":"60","author":"J Crook","year":"2004","unstructured":"Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G (2004) Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (1): 15\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"BFbjc2014197_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijrobp.2008.04.075","volume":"73","author":"J Crook","year":"2009","unstructured":"Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G (2009) Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 73 (2): 327\u2013333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"BFbjc2014197_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/1471-2407-10-675","volume":"10","author":"F Cuppone","year":"2010","unstructured":"Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nistic\u00f2 C, Ruggeri E, Sperduti I, Bracarda S, Pinnar\u00f2 P (2010) Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 10 (1): 675.","journal-title":"BMC Cancer"},{"issue":"7","key":"BFbjc2014197_CR30","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.292.7.821","volume":"292","author":"AV D'Amico","year":"2004","unstructured":"D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 292 (7): 821\u2013827.","journal-title":"JAMA"},{"issue":"3","key":"BFbjc2014197_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/sj.bjc.6602301","volume":"92","author":"D Dearnaley","year":"2005","unstructured":"Dearnaley D, Hall E, Lawrence D, Huddart R, Eeles R, Nutting C, Gadd J, Warrington A, Bidmead M, Horwich A (2005) Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (3): 488\u2013498.","journal-title":"Br J Cancer"},{"issue":"1","key":"BFbjc2014197_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","volume":"13","author":"D Dearnaley","year":"2012","unstructured":"Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13 (1): 43\u201354.","journal-title":"Lancet Oncol"},{"issue":"6","key":"BFbjc2014197_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","volume":"8","author":"DP Dearnaley","year":"2007","unstructured":"Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (6): 475\u2013487.","journal-title":"Lancet Oncol"},{"issue":"11","key":"BFbjc2014197_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","volume":"6","author":"JW Denham","year":"2005","unstructured":"Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (11): 841\u2013850.","journal-title":"Lancet Oncol"},{"issue":"5","key":"BFbjc2014197_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","volume":"12","author":"JW Denham","year":"2011","unstructured":"Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12 (5): 451\u2013459.","journal-title":"Lancet Oncol"},{"issue":"3","key":"BFbjc2014197_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7 (3): 177\u2013188.","journal-title":"Control Clin Trials"},{"key":"BFbjc2014197_CR37","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades A (2011) NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment: Forthcoming."},{"issue":"3","key":"BFbjc2014197_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/jama.299.3.289","volume":"299","author":"AV D\u2019Amico","year":"2008","unstructured":"D\u2019Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 299 (3): 289\u2013295.","journal-title":"JAMA"},{"issue":"6","key":"BFbjc2014197_CR39","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/S0022-5347(01)63235-X","volume":"159","author":"T Granfors","year":"1998","unstructured":"Granfors T, Modig H, Damber J-E, Tomic R (1998) Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 159 (6): 2030\u20132034.","journal-title":"J Urol"},{"issue":"2","key":"BFbjc2014197_CR40","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.juro.2006.03.092","volume":"176","author":"T Granfors","year":"2006","unstructured":"Granfors T, Modig H, Damber J-E, Tomic R (2006) Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 176 (2): 544\u2013547.","journal-title":"J Urol"},{"issue":"21","key":"BFbjc2014197_CR41","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","volume":"21","author":"GE Hanks","year":"2003","unstructured":"Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92\u201302. J Clin Oncol 21 (21): 3972\u20133978.","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2014197_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.07.1680","volume":"78","author":"WD Heemsbergen","year":"2010","unstructured":"Heemsbergen WD, Al-Mamgani A, Witte MG, Van Herk M, Pos FJ, Lebesque JV (2010) Urinary obstruction in prostate cancer patients from the dutch trial (68 gy vs 78 gy): Relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys 78 (1): 19\u201325.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"BFbjc2014197_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"A Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid H-P, van der Kwast T, Wiegel T (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59 (1): 61\u201371.","journal-title":"Eur Urol"},{"issue":"7414","key":"BFbjc2014197_CR44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327 (7414): 557.","journal-title":"BMJ"},{"issue":"15","key":"BFbjc2014197_CR45","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","volume":"26","author":"EM Horwitz","year":"2008","unstructured":"Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (15): 2497\u20132504.","journal-title":"J Clin Oncol"},{"issue":"2","key":"BFbjc2014197_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61 (2): 69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"BFbjc2014197_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56 (2): 106\u2013130.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"BFbjc2014197_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1012348","volume":"365","author":"CU Jones","year":"2011","unstructured":"Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. New Engl J Med 365 (2): 107\u2013118.","journal-title":"New Engl J Med"},{"key":"BFbjc2014197_CR49","unstructured":"PTH Julian, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The Cochrane Collaboration."},{"key":"BFbjc2014197_CR50","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.critrevonc.2012.12.002","volume":"84","author":"MA Kollmeier","year":"2012","unstructured":"Kollmeier MA, Zelefsky MJ (2012) How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol\/Hematol 84: e6\u2013e15.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"BFbjc2014197_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","volume":"70","author":"DA Kuban","year":"2008","unstructured":"Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (1): 67\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"BFbjc2014197_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0167-8140(03)00193-2","volume":"68","author":"DS Lamb","year":"2003","unstructured":"Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M (2003) Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol 68 (3): 255\u2013267.","journal-title":"Radiother Oncol"},{"issue":"3","key":"BFbjc2014197_CR53","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/01.ju.0000112979.97941.7f","volume":"171","author":"J Laverdiere","year":"2004","unstructured":"Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F (2004) The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171 (3): 1137\u20131140.","journal-title":"J Urol"},{"issue":"5","key":"BFbjc2014197_CR54","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0360-3016(97)00288-5","volume":"38","author":"CA Lawton","year":"1997","unstructured":"Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD (1997) Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 38 (5): 931\u2013939.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"BFbjc2014197_CR55","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","volume":"23","author":"CA Lawton","year":"2005","unstructured":"Lawton CA, Winter K, Grignon D, Pilepich MV (2005) Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 23 (4): 800\u2013807.","journal-title":"J Clin Oncol"},{"issue":"4","key":"BFbjc2014197_CR56","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","volume":"49","author":"CA Lawton","year":"2001","unstructured":"Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (4): 937\u2013946.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"BFbjc2014197_CR57","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades A (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Statist Med 23 (20): 3105\u20133124.","journal-title":"Statist Med"},{"key":"BFbjc2014197_CR58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1198\/016214505000001302","volume":"101","author":"G Lu","year":"2006","unstructured":"Lu G, Ades A (2006) Assessing evidence inconsistency in mixed treatment comparisons. J Am Statist Assoc 101: 447\u2013459.","journal-title":"J Am Statist Assoc"},{"issue":"25","key":"BFbjc2014197_CR59","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","volume":"23","author":"H Lukka","year":"2005","unstructured":"Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (25): 6132\u20136138.","journal-title":"J Clin Oncol"},{"issue":"16","key":"BFbjc2014197_CR60","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/sim.1201","volume":"21","author":"T Lumley","year":"2002","unstructured":"Lumley T (2002) Network meta\u2013analysis for indirect treatment comparisons. Statist Med 21 (16): 2313\u20132324.","journal-title":"Statist Med"},{"key":"BFbjc2014197_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1756-9966-28-117","volume":"28","author":"S Marzi","year":"2009","unstructured":"Marzi S, Saracino B, Petrongari MG, Arcangeli S, Gomellini S, Arcangeli G, Benassi M, Landoni V (2009) Modeling of alpha\/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res 28: 117.","journal-title":"J Exp Clin Cancer Res"},{"issue":"24","key":"BFbjc2014197_CR62","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/jnci\/djn414","volume":"100","author":"D Mauri","year":"2008","unstructured":"Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100 (24): 1780\u20131791.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"BFbjc2014197_CR63","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ijrobp.2013.07.041","volume":"87","author":"JM Michalski","year":"2013","unstructured":"Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary J-P, Morton GC, Parliament MB, Sandler HM (2013) Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 87 (5): 932\u2013938.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"BFbjc2014197_CR64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.acuro.2011.03.011","volume":"35","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid H-P, Van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Actas Urol\u00f3gicas Espa\u00f1olas 35 (10): 565\u2013579.","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"issue":"6","key":"BFbjc2014197_CR65","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0090-4295(98)00028-4","volume":"51","author":"LN Nguyen","year":"1998","unstructured":"Nguyen LN, Pollack A, Zagars GK (1998) Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 51 (6): 991\u2013997.","journal-title":"Urology"},{"issue":"11","key":"BFbjc2014197_CR66","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00066-009-1982-z","volume":"185","author":"D Norkus","year":"2009","unstructured":"Norkus D, Miller A, Kurtinaitis J, Haverkamp U, Popov S, Prott F-J, Valuckas KP (2009a) A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma. Strahlentherapie Und Onkologie 185 (11): 715\u2013721.","journal-title":"Strahlentherapie Und Onkologie"},{"issue":"6","key":"BFbjc2014197_CR67","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/medicina45060061","volume":"45","author":"D Norkus","year":"2009","unstructured":"Norkus D, Miller A, Plieskiene A, Janulionis E, Valuckas KP (2009b) A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response. Medicina (Kaunas 45 (6): 469\u2013475.","journal-title":"Medicina (Kaunas"},{"issue":"13","key":"BFbjc2014197_CR68","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","volume":"24","author":"ST Peeters","year":"2006","unstructured":"Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (13): 1990\u20131996.","journal-title":"J Clin Oncol"},{"issue":"4","key":"BFbjc2014197_CR69","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.ijrobp.2004.07.715","volume":"61","author":"ST Peeters","year":"2005","unstructured":"Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper P (2005) Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (4): 1019\u20131034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"BFbjc2014197_CR70","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1200\/JCO.1997.15.3.1013","volume":"15","author":"M Pilepich","year":"1997","unstructured":"Pilepich M, Caplan R, Byhardt R, Lawton C, Gallagher M, Mesic J, Hanks G, Coughlin C, Porter A, Shipley W (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (3): 1013\u20131021.","journal-title":"J Clin Oncol"},{"issue":"4","key":"BFbjc2014197_CR71","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S0090-4295(99)80053-3","volume":"45","author":"MV Pilepich","year":"1995","unstructured":"Pilepich MV, Sause WT, Shipley WU, Krall JM, Lawton CA, Grignon D, Al-Sarraf M, Abrams RA, Caplan R, John MJ (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45 (4): 616\u2013623.","journal-title":"Urology"},{"issue":"5","key":"BFbjc2014197_CR72","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","volume":"50","author":"MV Pilepich","year":"2001","unstructured":"Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (5): 1243\u20131252.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"BFbjc2014197_CR73","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","volume":"61","author":"MV Pilepich","year":"2005","unstructured":"Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85\u201331. Int J Radiat Oncol Biol Phys 61 (5): 1285\u20131290.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"31","key":"BFbjc2014197_CR74","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","volume":"31","author":"A Pollack","year":"2013","unstructured":"Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31 (31): 3860\u20133868.","journal-title":"J Clin Oncol"},{"issue":"23","key":"BFbjc2014197_CR75","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1200\/JCO.2000.18.23.3904","volume":"18","author":"A Pollack","year":"2000","unstructured":"Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (23): 3904\u20133911.","journal-title":"J Clin Oncol"},{"issue":"5","key":"BFbjc2014197_CR76","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","volume":"53","author":"A Pollack","year":"2002","unstructured":"Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (5): 1097\u20131105.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"BFbjc2014197_CR77","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0360-3016(95)02103-5","volume":"34","author":"A Pollack","year":"1996","unstructured":"Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen II (1996) Conventional vs conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34 (3): 555\u2013564.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"BFbjc2014197_CR78","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","volume":"26","author":"M Roach","year":"2008","unstructured":"Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26 (4): 585\u2013591.","journal-title":"J Clin Oncol"},{"issue":"4","key":"BFbjc2014197_CR79","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach III","year":"2006","unstructured":"Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (4): 965\u2013974.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"BFbjc2014197_CR80","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti G, Higgins JP, Ades A, Ioannidis JP (2008) Evaluation of networks of randomized trials. Statist Methods Med Res 17 (3): 279\u2013301.","journal-title":"Statist Methods Med Res"},{"issue":"8","key":"BFbjc2014197_CR81","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jclinepi.2008.10.001","volume":"62","author":"G Salanti","year":"2009","unstructured":"Salanti G, Marinho V, Higgins J (2009) A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 62 (8): 857\u2013864.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"BFbjc2014197_CR82","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","volume":"23","author":"JR Sathya","year":"2005","unstructured":"Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (6): 1192\u20131199.","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2014197_CR83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0360-3016(95)00063-5","volume":"32","author":"WU Shipley","year":"1995","unstructured":"Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ (1995) Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32 (1): 3\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"BFbjc2014197_CR84","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63 (1): 11\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"BFbjc2014197_CR85","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) Bayesian measures of model complexity and fit. J Royal Statist Soc B 64 (4): 583\u2013639.","journal-title":"J Royal Statist Soc B"},{"issue":"3","key":"BFbjc2014197_CR86","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0360-3016(00)00700-8","volume":"48","author":"MR Storey","year":"2000","unstructured":"Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I (2000) Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (3): 635\u2013642.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"BFbjc2014197_CR87","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.ijrobp.2008.07.024","volume":"73","author":"L Strigari","year":"2009","unstructured":"Strigari L, Arcangeli G, Arcangeli S, Benassi M (2009) Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. Int J Radiat Oncol Biol Phys 73 (5): 1454\u20131460.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"BFbjc2014197_CR88","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0895-4356(00)00311-5","volume":"54","author":"TA Trikalinos","year":"2001","unstructured":"Trikalinos TA, Ioannidis J (2001) Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol 54 (3): 245\u2013252.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"BFbjc2014197_CR89","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","volume":"74","author":"GA Viani","year":"2009","unstructured":"Viani GA, Stefano EJ, Afonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74 (5): 1405\u20131418.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"BFbjc2014197_CR90","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","volume":"81","author":"EE Yeoh","year":"2011","unstructured":"Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J (2011) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81 (5): 1271\u20131278.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"BFbjc2014197_CR91","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0360-3016(02)04146-9","volume":"55","author":"EE Yeoh","year":"2003","unstructured":"Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, Penniment MG, Borg MF (2003) Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 55 (4): 943\u2013955.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"BFbjc2014197_CR92","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.ijrobp.2006.06.005","volume":"66","author":"EE Yeoh","year":"2006","unstructured":"Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P (2006) Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (4): 1072\u20131083.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"BFbjc2014197_CR93","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/0360-3016(88)90383-5","volume":"14","author":"GK Zagars","year":"1988","unstructured":"Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH (1988) Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14 (6): 1085\u20131091.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"BFbjc2014197_CR94","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","volume":"28","author":"AL Zietman","year":"2010","unstructured":"Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09. J Clin Oncol 28 (7): 1106\u20131111.","journal-title":"J Clin Oncol"},{"issue":"10","key":"BFbjc2014197_CR95","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","volume":"294","author":"AL Zietman","year":"2005","unstructured":"Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294 (10): 1233\u20131239.","journal-title":"JAMA"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014197","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:22:48Z","timestamp":1684416168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,15]]},"references-count":95,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFbjc2014197"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.197","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,15]]},"assertion":[{"value":"6 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}